2024
Perspectives on benefits and risks of creation of an “injection drug use” billing code
Sundaram G, Sato T, Goodman-Meza D, Haddad M, Thakarar K, Feinberg J, Springer S, Barton K, Butler N, Eaton E, Wurcel A. Perspectives on benefits and risks of creation of an “injection drug use” billing code. Journal Of Substance Use And Addiction Treatment 2024, 164: 209392. PMID: 38735482, DOI: 10.1016/j.josat.2024.209392.Peer-Reviewed Original ResearchInjection drug useSubstance use disordersInternational Classification of DiseasesIncreased riskICD-10 codesDrug useClassification of DiseasesHealthcare utilizationHealth servicesIncreased risk of overdoseFinancial reimbursementInternational ClassificationHealthcare systemRisk of overdoseTreatment servicesICD codesIdentifying peopleWell-beingPWIDUse disorderSystem of resource allocationHealthRiskImproved systemPotential benefits
2021
Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions
Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, Springer SA. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. International Journal Of Drug Policy 2021, 96: 103283. PMID: 34020864, PMCID: PMC8568621, DOI: 10.1016/j.drugpo.2021.103283.Peer-Reviewed Original ResearchConceptsMobile health unitOpioid use disorderHepatitis COUD preventionTreatment servicesInfectious diseasesHepatitis C virus (HCV) managementOpioid use disorder preventionCJ-involved individualsCriminal justice-involved individualsCJ systemHarm reduction servicesImproving HIVCare cascadePatient navigationJustice-involved individualsHealth unitsUse disordersHIVReduction servicesSubstance usePreventionDisorder preventionCommunity agenciesTreatment
2020
Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda
Springer SA, Barocas J, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda. The Journal Of Infectious Diseases 2020, 222: s230-s238. PMID: 32877568, PMCID: PMC7467230, DOI: 10.1093/infdis/jiz673.Peer-Reviewed Original ResearchMeSH KeywordsBacteremiaCommunicable Disease ControlFederal GovernmentHealth PolicyHepatitis BHepatitis CHIV InfectionsHuman RightsHumansIllicit DrugsInfectious Disease MedicineIntersectoral CollaborationInvasive Fungal InfectionsOpioid EpidemicPatient AdvocacyPreventive Health ServicesPublic Health AdministrationSocieties, MedicalState GovernmentSubstance-Related DisordersUnited StatesConceptsIllicit drug useInfectious diseasesAddiction specialistsDrug useSubstance use disorder treatmentUse disorder treatmentHarm reduction toolHIV physiciansInfectious complicationsEvidence-based practiceHIV epidemicOpioid epidemicCare continuumAssociated InfectionsTreatment servicesDisorder treatmentOpioid crisisDiseaseIDSAReview programEpidemicFurther disseminationHuman rights-based responseAdvocacy agendaMorbidity